The most common cardiovascular adverse effects caused by VEGF pathway inhibitors are hypertension, which is considered to be associated with an imbalance in vasoconstrictor-diastolic homeostasis (43), structural changes in the microvasculature (44), and an increase in oxidative stress (45). This evidence concerns the gene VEGFA and Hypertension.